
Sign up to save your podcasts
Or


December 4, 2001. A bad day, indeed. That’s the day the FDA issued a black box warning for droperidol, citing evidence of QT prolongation, Torsades de Pointes, and death. This was a surprise warning because droperidol had been extensively used by emergency medicine and anesthesiology for decades without apparent problems. Since this bad day, we’ve essentially been without droperidol. Fortunately, it’s back! Before we use it again, we should look at what got this drug on the FDA’s radar. Dr. Jarvis reviews the literature about the “evidence” behind the warning and describes how his systems will be bringing droperidol back into practice.
By Long Pause Media | FlightBridgeED4.9
131131 ratings
December 4, 2001. A bad day, indeed. That’s the day the FDA issued a black box warning for droperidol, citing evidence of QT prolongation, Torsades de Pointes, and death. This was a surprise warning because droperidol had been extensively used by emergency medicine and anesthesiology for decades without apparent problems. Since this bad day, we’ve essentially been without droperidol. Fortunately, it’s back! Before we use it again, we should look at what got this drug on the FDA’s radar. Dr. Jarvis reviews the literature about the “evidence” behind the warning and describes how his systems will be bringing droperidol back into practice.

125 Listeners

1,877 Listeners

386 Listeners

21 Listeners

97 Listeners

229 Listeners

268 Listeners

274 Listeners

39 Listeners

146 Listeners

44 Listeners

19 Listeners

891 Listeners

213 Listeners

8 Listeners